Press Releases

Company News
View Summary Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
May 21, 2013 		PDF 22.2 KB
View Summary Genomic Health Announces Medicare Expanded Coverage Policy for Oncotype DX® Breast Cancer Test to Include Ductal Carcinoma in Situ (DCIS) Diagnosis
May 10, 2013 		PDF 15.5 KB
View Summary Genomic Health Announces Availability of Oncotype DX® Prostate Cancer Test with Potential to Triple the Number of Patients Who Can Confidently Choose Active Surveillance and Avoid Side Effects of Invasive Treatments
May 8, 2013 		PDF 22.4 KB
View Summary Genomic Health to Present at Bank of America Merrill Lynch Health Care Conference
May 7, 2013 		PDF 15.7 KB
View Summary Genomic Health and ECOG-ACRIN Cancer Research Group Announce Publication of Positive DCIS Validation Study in the Journal of the National Cancer Institute
May 2, 2013 		PDF 22.1 KB
View Summary Genomic Health Announces First Quarter 2013 Financial Results and Business Progress
May 2, 2013 		PDF 26.5 KB
View Summary Genomic Health Announces Investor Webcast and Conference Call to Review Positive Clinical Validation and Development of the Oncotype DX® Prostate Cancer Test on Wednesday, May 8, 2013
May 1, 2013 		PDF 18.6 KB
View Summary Genomic Health to Announce First Quarter 2013 Financial Results and Host Conference Call on Thursday, May 2, 2013
Apr 25, 2013 		PDF 16.1 KB
View Summary Genomic Health Announces Publication of Second Positive Validation of Oncotype DX Colon Cancer Test Confirming Its Value Beyond Conventional Markers
Apr 17, 2013 		PDF 18.0 KB
View Summary Genomic Health to Address One of the Most Significant Needs in Men's Health with the Oncotype DX® Prostate Cancer Test
Apr 3, 2013 		PDF 19.3 KB
View Summary Genomic Health Presents Twenty Two International Studies Demonstrating Worldwide Adoption and Value of Oncotype DX® Breast Cancer Test
Mar 15, 2013 		PDF 24.9 KB
View Summary Genomic Health Announces Positive Results from Large Study of Oncotype DX® to Quantify Risk of Loco-Regional Recurrence in Node-positive Breast Cancer Patients and Acceptance of Oncotype DX DCIS Validation Study for Publication
Mar 13, 2013 		PDF 18.4 KB
View Summary Genomic Health Announces Results from Two Studies Demonstrating Innovations in Next Generation Sequencing From Paraffin Tissue, Enhancing Understanding of Tumor Biology
Feb 25, 2013 		PDF 19.0 KB
View Summary Genomic Health Announces Year-End 2012 Financial Results, Provides 2013 Financial Outlook
Feb 6, 2013 		PDF 29.3 KB
View Summary Genomic Health to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, February 6, 2013
Jan 30, 2013 		PDF 16.0 KB
View Summary Genomic Health Announces New Evidence Further Demonstrating Clinical Utility and Cost-Effectiveness of Oncotype DX in Colon Cancer
Jan 23, 2013 		PDF 19.0 KB
View Summary Genomic Health to Present at the J.P. Morgan Healthcare Conference
Dec 21, 2012 		PDF 15.2 KB
View Summary Genomic Health Announces Results from Six Studies Demonstrating Unique Value of the Oncotype DX Breast Cancer Test in Early Stage Breast Cancer
Dec 10, 2012 		PDF 19.0 KB
View Summary Genomic Health Announces Presentation of Six Studies at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium
Nov 28, 2012 		PDF 17.8 KB
View Summary Genomic Health to Present at Two Upcoming Investor Conferences
Nov 9, 2012 		PDF 15.6 KB
Showing 1-20 of 248 Page: 1 2 3 4 5 ... 13  Next 20


  • ASCO® is a registered trademark of the American Society of Clinical Oncology. ASCO does not endorse any product or therapy. ® is a registered trademark of the National Comprehensive Cancer Network. The NCCN does not endorse any product or therapy.

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

Shareholder Tools



DISCLAIMER

The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.